Shipment company

Isracann Bioscience makes it easy to ship cannabis genetics

VANCOUVER, British Columbia, Sept. 14, 2022 (GLOBE NEWSWIRE) — Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”), a multi-faceted Israeli company that aims to become a high-quality, low-cost cannabis producer/distributor, is pleased to announce that it has facilitated its first shipment of cannabis strains to Israel.

The deal for the genetics is made directly between United Greeneries Ltd, a licensed Canadian producer of high-caliber craft cannabis, and Intelicanna, a licensed Israeli medical cannabis producer and brand. Three initial premium strains are included in the deal, with the possibility of additional strains. Under a revenue-sharing agreement, United Greeneries will be responsible for cultivation and genetic support, with in-country support provided by Isracann.

“Israel is the largest importer of Canadian cannabis in the world,” notes CEO Phil Floucault. “The main reason for this is that the domestic market does not have the high THC strains available outside the country. I am delighted that Isracann, through our agreement with United Greeneries, was able to arrange this shipment of genetics to Intelicanna and we look forward to expanding this offering.United Greeneries Ltd. continues to supply some of the most potent Sativa and Indica strains to the Canadian domestic market and seeks to help Intelicanna do the same in Israel.

Since 2021, Intelicanna has been cultivating and selling medicinal cannabis for the Israeli market under the Intelicanna brand. Their HaSharon facility is one of the most advanced in Israel and comprises 5,500 m2 hybrid greenhouse with full light, shade and climate control.

Phil Floucault continues: “This first shipment should arrive in Israel in the short term. We worked with Intelicanna to get everything ready to receive the clones and speed up the scaling process to full production. In a short time, quality Canadian cannabis will be grown in Israel. »

On behalf of the Board of Directors

Phil Floucault

Philippe Floucault
CEO and President

About Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF)
Isracann is a multidisciplinary cannabis-focused producer and product developer with agricultural cannabis production assets based in Israel and a Canadian natural health drug development and production arm. Along with a focus on initial retail sales in Canada and becoming a leading cannabis producer offering domestic Israeli production at low cost, the company aims to bring natural health medicines to market in Canada and leverage deals in Israel to import/export opportunities and the cultivation of marijuana for medical purposes. For more information, visit:

Empire Communications Group
+1 (604) 343-2724
[email protected]

Forward-looking information
This press release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends to ”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “could”, “could” or “should” occur. Forward-looking statements may include, but are not limited to, statements relating to the Company’s delivery of products to market in the fourth quarter of 2022 and the Company’s plans to expand its distribution network in Canada and North America. . The forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. All forward-looking statements contained in this press release are made as of the date of this press release. The forward-looking statements contained herein are also generally subject to assumptions and risks and uncertainties that are described from time to time in the Company’s filings from time to time with the CSE, the British Columbia Securities Commission, the Alberta Securities Commission and the Ontario Securities Commission. Although Isracann believes that the expectations expressed in these forward-looking statements are based on reasonable assumptions, these statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Isracann expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CSE does not accept responsibility for the adequacy or accuracy of this release.